GlaxoSmithKline PLC

36.60-0.2800-0.76%Vol 8.53M1Y Perf -13.59%
Dec 8th, 2022 16:00 DELAYED
BID36.56 ASK37.00
Open36.36 Previous Close36.88
Pre-Market- After-Market36.56
 - -  -0.04 -0.11%
Target Price
61.42 
Analyst Rating
Hold 3.29
Potential %
67.81 
Finscreener Ranking
★★     46.17
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     47.39
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     57.29
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★+     36.43
Price Range Ratio 52W %
43.96 
Earnings Rating
Strong Sell
Market Cap74.92B 
Earnings Date
2nd Nov 2022
Alpha0.00 Standard Deviation0.05
Beta0.61 

Today's Price Range

36.3137.00

52W Range

28.4746.97

5 Year PE Ratio Range

0.000090.80

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
3.54%
1 Month
12.89%
3 Months
14.77%
6 Months
-14.96%
1 Year
-13.59%
3 Years
-19.79%
5 Years
4.07%
10 Years
-1.33%

TickerPriceChg.Chg.%
GSK36.60-0.2800-0.76
AAPL142.651.71001.21
GOOG93.95-1.2000-1.26
MSFT247.403.03001.24
XOM104.420.77000.74
WFC42.580.13000.31
JNJ177.200.03000.02
FB196.640.99000.51
GE83.63-1.3700-1.61
JPM132.881.38001.05
 
ProfitabilityValueIndustryS&P 500US Markets
64.80
18.10
25.50
14.70
42.56
RevenueValueIndustryS&P 500US Markets
43.04B
21.17
2.82
3.68
DividendsValueIndustryS&P 500US Markets
3.61
1.27
1.73
1.04
Payout ratio91.00
Earnings HistoryEstimateReportedSurprise %
Q03 20220.901.0921.11
Q02 20220.760.8714.47
Q01 20220.961.1014.58
Q04 20210.790.868.86
Q03 20211.001.2626.00
Q02 20210.680.9945.59
Q01 20210.790.790.00
Q04 20200.700.62-11.43
Earnings Per EndEstimateRevision %Trend
12/2022 QR0.62-22.50Negative
12/2022 FY3.26-3.26Negative
3/2023 QR0.89-19.09Negative
12/2023 FY3.40-4.49Negative
Next Report Date-
Estimated EPS Next Report0.91
Estimates Count4
EPS Growth Next 5 Years %8.80
Volume Overview
Volume8.53M
Shares Outstanding2.05M
Shares Float2.02B
Trades Count52.70K
Dollar Volume312.78M
Avg. Volume8.34M
Avg. Weekly Volume11.70M
Avg. Monthly Volume6.75M
Avg. Quarterly Volume6.58M

GlaxoSmithKline PLC (NYSE: GSK) stock closed at 36.6 per share at the end of the most recent trading day (a -0.76% change compared to the prior day closing price) with a volume of 8.53M shares and market capitalization of 74.92B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 99437 people. GlaxoSmithKline PLC CEO is Emma N. Walmsley.

The one-year performance of GlaxoSmithKline PLC stock is -13.59%, while year-to-date (YTD) performance is -17.01%. GSK stock has a five-year performance of 4.07%. Its 52-week range is between 28.465 and 46.97, which gives GSK stock a 52-week price range ratio of 43.96%

GlaxoSmithKline PLC currently has a PE ratio of 4.30, a price-to-book (PB) ratio of 4.49, a price-to-sale (PS) ratio of 1.66, a price to cashflow ratio of 7.00, a PEG ratio of 2.32, a ROA of 17.67%, a ROC of 39.71% and a ROE of 98.82%. The company’s profit margin is 42.56%, its EBITDA margin is 25.50%, and its revenue ttm is $43.04 Billion , which makes it $21.17 revenue per share.

Of the last four earnings reports from GlaxoSmithKline PLC, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.91 for the next earnings report. GlaxoSmithKline PLC’s next earnings report date is -.

The consensus rating of Wall Street analysts for GlaxoSmithKline PLC is Hold (3.29), with a target price of $61.42, which is +67.81% compared to the current price. The earnings rating for GlaxoSmithKline PLC stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

GlaxoSmithKline PLC has a dividend yield of 3.61% with a dividend per share of $1.27 and a payout ratio of 91.00%.

GlaxoSmithKline PLC has a Buy technical analysis rating based on Technical Indicators (ADX : 7.07, ATR14 : 1.00, CCI20 : 135.71, Chaikin Money Flow : 0.03, MACD : 1.14, Money Flow Index : 56.63, ROC : 9.45, RSI : 66.17, STOCH (14,3) : 55.43, STOCH RSI : 0.12, UO : 59.52, Williams %R : -44.57), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of GlaxoSmithKline PLC in the last 12-months were: Anne Beal (Buy at a value of $39 837), Charles A. Bancroft (Buy at a value of $258 868), Emma N. Walmsley (Buy at a value of $132 792 496), Emma N. Walmsley (Sold 182 556 shares of value $3 166 993 ), Hal V Barron (Buy at a value of $2 518 164), Hal V Barron (Sold 198 216 shares of value $4 287 661 ), Harry C Dietz (Buy at a value of $44 359), Iain James Mackay (Buy at a value of $21 676 738), Jesse Goodman (Buy at a value of $57 861), Jonathan Richard Symonds (Buy at a value of $173 902), Laurie H. Glimcher (Buy at a value of $177 778), Lynn Laverty Elsenhans (Buy at a value of $31 777), Manvinder Singh Banga (Buy at a value of $29 058), Urs Rohner (Buy at a value of $27 199), Vivienne Cox (Buy at a value of $25 322)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
1 (14.29 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
6 (85.71 %)
7 (100.00 %)
6 (85.71 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (14.29 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.29
Hold
3.00
Hold
2.71

GlaxoSmithKline PLC

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

CEO: Emma N. Walmsley

Telephone: +44 2080475000

Address: 980 Great West Road, Brentford TW8 9GS, Middlesex, GB

Number of employees: 99 437

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

58%42%

Bearish Bullish

59%41%

TipRanks News for GSK

Tue, 08 Nov 2022 13:10 GMT Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

- TipRanks. All rights reserved.

Tue, 19 Jul 2022 09:02 GMT What Does the Haleon Spinoff Mean for GSK Shareholders

- TipRanks. All rights reserved.

News

Stocktwits